ZYNE | Zynerba Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2600 - 1.3400
52 Week Range	0.2500 - 1.4000
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	861,742
Average Volume	1,043,239
Shares Outstanding	53,939,400
Market Cap	70,121,220
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2015-08-05

Valuation
Profitability
Growth
Health
P/E Ratio	-1.65
Forward P/E Ratio	N/A
EPS	-0.79
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	25
Country	USA
Website	ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

ZYNE's peers: CARA

*Chart delayed

Analyzing fundamentals for ZYNE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ZYNE Fundamentals page.

Watching at ZYNE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ZYNE Technicals page.